广东省人民医院
Guangdong Provincial People's Hospital
在本站收录的 53 种疾病中,这家医院列在其中 24 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
广东省人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma14 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma19 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma54 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer21 篇牵头论文牵头 1 项开放试验
- 肝母细胞瘤Hepatoblastoma1 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 脊索瘤Chordoma1 篇牵头论文
- 骨肉瘤Osteosarcoma11 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
- 神经母细胞瘤Neuroblastoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma3 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia1 篇牵头论文
- β 地中海贫血Beta thalassaemia1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder3 篇牵头论文
- IgG4相关性疾病IgG4-related disease3 篇牵头论文
- 重症肌无力Myasthenia gravis1 篇牵头论文
- 大动脉炎Takayasu arteritis0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 法布雷病Fabry disease1 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy8 篇牵头论文牵头 1 项开放试验
- 原发性胆汁性胆管炎Primary biliary cholangitis4 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
未列出的收录疾病:尤文肉瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。
- 牵头的开放试验
- 0
- 正在或即将招募
广州有 23 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- 分期
- II期
- 开始
- 2025-06
- 登记号
- NCT07070479
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心中山、广州、珠海、长沙
- 正在招募Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- 分期
- 不分期
- 开始
- 2023-06
- 登记号
- NCT05892354
年龄 18 岁 至 70 岁(登记的条件)
牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文14
- Chemoimmunotherapy as induction treatment in concurrent chemoradiotherapy for patients with nasopharyngeal carcinoma stage IVa.
- Integrating pan-immune-inflammation value into personalized survival prediction of nasopharyngeal carcinoma: a large-scale long-term retrospective study.
- Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
- Prediction of Recurrence using a Stacked Denoising Autoencoder and Multifaceted Feature Analysis of Pretreatment MRI in Patients with Nasopharyngeal Carcinoma.
- Cholesterol-to-lymphocyte ratio (CLR)-based nomogram as a prognostic tool in nasopharyngeal carcinoma: a large-scale long-term retrospective study.
- Application of Large Language Models in TN Staging and Treatment Response Evaluation for Patients With Nasopharyngeal Carcinoma: A Comparative Performance Analysis of ChatGPT-4o-Latest and DeepSeek-V3-0324.
- Key Risk Factors for Postoperative Hypotension in Nasopharyngeal Carcinoma Patients After Endoscopic Surgery: A Retrospective Study.
- ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.
- Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.
- A glutathione-sensitive cationic polymer delivery of CRISPR-Cas9 RNA plasmid for targeting nasopharyngeal carcinoma gene therapy.
- Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison.
- Using the non-distortion IVIM to reduce the need for contrast agents in nasopharyngeal MRI.
- Effects of combination docetaxel with NO treatment to enhance the anti-nasopharyngeal carcinoma efficiency in vitro and in vivo.
- Long-Term Outcomes of Cochlear Implantation in Irradiated Ears of Nasopharyngeal Carcinoma Patients.
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
PubMed 以外找到的论文(未计入)10
- 1376P A comprehensive overview of immune-related adverse events induced by immune checkpoint inhibitors in nasopharyngeal carcinoma
- Efficacy and safety of induction chemoimmunotherapy versus induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A meta-analysis.
- 402O Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
- 455P A real-world study: Induction chemoimmunotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with stage IVa
- Microplastics Antagonize the Therapeutic Effect of Curcumin on Nasopharyngeal Carcinoma Through Inhibiting the Apoptosis Pathway
- SICNet: Learning selective inter-slice context via Mask-Guided Self-knowledge distillation for NPC segmentation
- Enhanced Multi-Task Nasopharyngeal Carcinoma Recurrence Prediction by Knowledge Distillation with Loss-Balanced Weighting Strategy
- Risk Factors Analysis of Post Anesthesia Induction Hypotension in Patients with Recurrent Nasopharyngeal Carcinoma
- Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
- Effect of Exercise on Sternoceleidomastoid Muscular Fibrosis after Radiotherapy for Nasopharyngeal Carcinoma Patients Analyzed by Shear-Wave Elastography
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.7%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 11 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文19
- Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy.
- ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma.
- m6A-mediated circG3BP1 translocation to stress granules promotes nucleation and senescence-linked chemoresistance.
- The mechanism of high mobility group box-1 in the proliferation and macrophage polarization in esophageal squamous cell carcinoma cells.
- Co-Infection by Porphyromonas gingivalis and Fusobacterium nucleatum Increases PD-L1 Expression in Esophageal Cancer Tissues.
- Decoding tumor stage by peritumoral and intratumoral radiomics in resectable esophageal squamous cell carcinoma.
- ASO Author Reflections: Enhancing Treatment Outcomes in Unresectable Esophageal Squamous Cell Carcinoma Through Immunochemotherapy.
- Induction Immunochemotherapy Yields a Higher Conversion Rate and Better Overall Survival than Chemotherapy in Initially Unresectable Esophageal Squamous Cell Carcinoma.
- Lymphatic endothelial cell-mediated accumulation of CD177+Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma.
- Early and Persistent Dysphagia Relief Predicts Tumor Response in Esophageal Squamous Cell Carcinoma Patients Treated with Immunochemotherapy.
- PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
- Dissecting T-cell heterogeneity in esophageal squamous cell carcinoma reveals the potential role of LAIR2 in antitumor immunity.
- Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma.
- COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy.
- Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data".
- Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models.
- Predictive value of the presence of Prevotella and the ratio of Porphyromonas gingivalis to Prevotella in saliva for esophageal squamous cell carcinoma.
- Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro).
- Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
- Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.
- The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer
- Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
- Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
- A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)19
- Alternative dosing regimens of tislelizumab proposed using modeling and simulation.
- 418P A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma
- 593. DEEP LEARNING-BASED PROGNOSTIC MODEL INTEGRATING TUMOR-INFILTRATING LYMPHOCYTES FOR ESOPHAGEAL CANCER: A MULTICENTER RETROSPECTIVE COHORT STUDY
- MO57-3 Effect of immunochemotherapy time-of-day infusion, sequence and interval on prognosis of advanced esophageal cancer
- 367. SPATIAL ORGANIZATION OF TUMOR-INFILTRATING LYMPHOCYTES PREDICTS PROGNOSIS OF PATIENTS WITH ESOPHAGEAL CANCER RECEIVING IMMUNOTHERAPY—A DEEP-LEARNING APPROACH
- Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Comparison of efficacy and safety of neoadjuvant regimens for resectable esophageal squamous cell carcinoma: A meta-analysis.
- Identification of secretory factors associated with suppressive tumor microenvironment in esophageal cancer
- Induction immunochemotherapy conversion rate and survival outcomes versus chemotherapy in initially unresectable esophageal squamous cell carcinoma.
- Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.
- Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.
- One-day preoperative systemic treatment regimen outcompetes five-day regimen in potentially resectable esophageal squamous cancer
- 190P Transcriptomic molecular subtypes of esophageal squamous cell carcinoma predicted the prognosis and efficacy of neo-adjuvant immunotherapy
- Analysis of DNA damage response gene signature for prognosis prediction of esophageal squamous cell carcinoma.
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 54 篇,占 0.4%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 14 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
- 分期
- II期
- 开始
- 2023-09
- 登记号
- NCT05954897
年龄 18 岁 至 未注明(登记的条件)
牵头:广东省人民医院广州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文54
- Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma.
- Mechanism of d-Glucaro-1,4-lactone enhancing the anticancer efficacy of lenvatinib via the IFN-γ-STAT3-PD-L1 signaling pathway in hepatocellular carcinoma.
- Liver diseases, transaminases, and hepatobiliary-pancreatic cancer risk: a cohort and Mendelian randomisation study using data from UK Biobank.
- AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity.
- DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma.
- Development and validation of interpretable machine learning model for pre-treatment predicting the response to targeted and immune therapy in hepatocellular carcinoma.
- Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study.
- Anti-Hepatocellular Carcinoma Effect of Jianpi Huayu Formula: Revealing the Molecular Mechanisms of the CXCR4 - Smad2/3 Pathway in Regulating Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition.
- Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma.
- ENO1-BACE2-mediated LDLR cleavage promotes liver cancer progression by remodelling cholesterol metabolism.
- Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming.
- TPX2 lactylation is required for the cell cycle regulation and hepatocellular carcinoma progression.
- Transcriptomic analysis reveals the potential role of TOE1 in hepatocellular carcinoma.
- Near-Infrared II Fluorescence Imaging Highlights Tumor Angiogenesis in Hepatocellular Carcinoma with a VEGFR-Targeted Probe.
- Predicting prognosis, immune landscape, and drug targets with a novel signature for hepatocellular carcinoma.
- Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection.
- Quercetin-induced degradation of RhoC suppresses hepatocellular carcinoma invasion and metastasis.
- Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.
- A commentary on 'Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: a randomised controlled trial'.
- Commentary on 'Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis'.
- Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy.
- Mechanistic insights into xanthomicrol as the active anti-HCC ingredient of Phytolacca acinosa Roxb.: A network pharmacology analysis and transcriptomics integrated experimental verification.
- Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8+ T cells in hepatocellular carcinoma.
- Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.
- Citrullination modulation stabilizes HIF-1α to promote tumour progression.
- HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression.
- Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion.
- EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β.
- The genetic liability to rheumatoid arthritis may decrease hepatocellular carcinoma risk in East Asian population: a Mendelian randomization study.
- Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
- Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma.
- Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy.
- All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis.
- Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma.
- CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect.
- Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion.
- Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
- Albumin-Bilirubin Score to Predict Outcomes in Patients with Idiopathic Dilated Cardiomyopathy.
- Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184.
- Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression.
- A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma.
- Preoperative prediction of intra-tumoral tertiary lymphoid structures based on CT in hepatocellular cancer.
- Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
- An injectable thermosensitive hydrogel loaded with a theranostic nanoprobe for synergistic chemo-photothermal therapy for multidrug-resistant hepatocellular carcinoma.
- Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.
- Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
- Prediction of Microvascular Invasion of Hepatocellular Carcinoma Based on Preoperative Diffusion-Weighted MR Using Deep Learning.
- Predictive value of a novel lncRNA LINC02518 in evaluating the prognosis of patients with hepatocellular carcinoma.
- Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.
- HBO1 overexpression is important for hepatocellular carcinoma cell growth.
- Association between hepatitis B and E virus infection and hepatocellular carcinoma risk.
- Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection: A meta-analysis including 4,092 patients.
- DNase1L3 suppresses hepatocellular carcinoma growth via inhibiting complement autocrine effect.
- miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A.
中文论文(未计入)4
- Identification of prognosis-related key genes in hepatocellular carcinoma based on bioinformatics analysis.
- [Research progress of radiomics in hepatocellular carcinoma].
- [Fontan-associated liver disease current status and transplantation consideration].
- [Value of radiomics model based on dynamic contrast-enhanced magnetic resonance imaging in differentiation fat-poor angiomyolipoma from alpha-fetoprotein-negative hepatocellular carcinoma in the background of non-cirrhotic liver].
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
- Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
- Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors
- Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
- Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
- Urea Cream Treatment Sorafenib-Associated HSFR in HCC
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.2%。
广州有 16 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 8
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
- 分期
- II期
- 开始
- 2026-03
- 登记号
- NCT07486310
年龄 18 岁 至 75 岁(登记的条件)
牵头:广东省人民医院广州
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07700979
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、广州
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
- 正在招募Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
- 分期
- 未注明
- 开始
- 2023-01
- 登记号
- NCT05722275
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、太原、广州、昆明、福州、郑州
- 正在招募Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- II期
- 开始
- 2023-11
- 登记号
- NCT06155383
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州
- 正在招募Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
- 分期
- II期
- 开始
- 2022-01
- 登记号
- NCT04840264
年龄 18 岁 至 75 岁(登记的条件)
牵头:中山大学附属第六医院;另有 1 家列出的医院为研究中心广州
- 正在招募OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- 分期
- 不分期
- 开始
- 2022-09
- 登记号
- NCT05450835
年龄 18 岁 至 75 岁(登记的条件)
牵头:南方医科大学南方医院;另有 7 家列出的医院为研究中心广州、汕头、沈阳、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文21
- Multitask Deep Learning Based on Longitudinal CT Images Facilitates Prediction of Lymph Node Metastasis and Survival in Chemotherapy-Treated Gastric Cancer.
- EGR4 transcriptionally upregulates GDF15 to promote gastric cancer metastasis.
- CXCL12 expression and the survival of patients with gastric cancer: a meta-analysis.
- Integrative analysis of bulk and single-cell sequencing reveals TNFSF9 as a potential regulator in microsatellite instability stomach adenocarcinoma.
- Role of m7G modification regulators as biomarkers in gastric cancer subtyping and precision immunotherapy.
- LGALS9B stabilizes EEF1D protein and activates the PI3K/AKT signaling pathway to promote gastric cancer occurrence and metastasis.
- Diagnostic challenges of rarely well-differentiated adenocarcinoma of the stomach.
- Single-cell RNA sequencing analysis revealed the immunosuppressive remodeling of tumor-associated macrophages mediated by the MIF-CD74 axis in gastric cancer.
- Hepatic Portal Venous Gas and Pneumatosis Intestinalis Associated With Early Oral Feeding After Laparoscopic Total Gastrectomy.
- KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer.
- Identification of chronic non-atrophic gastritis and intestinal metaplasia stages in the Correa's cascade through machine learning analyses of SERS spectral signature of non-invasively-collected human gastric fluid samples.
- Comparative single-cell analysis reveals heterogeneous immune landscapes in adenocarcinoma of the esophagogastric junction and gastric adenocarcinoma.
- GLT8D2 is a prognostic biomarker and regulator of immune cell infiltration in gastric cancer.
- The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer.
- m6A modification enhances the stability of CDC25A promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle.
- Prognostic value of a new staging system for adenocarcinoma of the esophagogastric junction after preoperative radiation therapy.
- Lymph node evaluation after neoadjuvant therapy for patients with adenocarcinoma of the esophagogastric junction.
- Clinical characteristics and prognostic outcomes for adenocarcinoma of esophagogastric junction in early-onset patients: a population-based appraisal.
- Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.
- Evaluation of proton pump inhibitors and risks of gastric cancer.
- The ratio of serum C-reactive protein level on postoperative day 3 to day 2 is a good marker to predict postoperative complications after laparoscopic radical gastrectomy for gastric cancer.
中文论文(未计入)3
- [High expression of CREM is associated with poor prognosis in gastric cancer patients].
- [Application of laparoscopic and open gastrectomy in enhanced recovery after surgery for gastric cancer: analysis of data from multiple centers in China].
- [Expression of nicotinamide-N-methyltransferase in gastric cancer and its biological and clinicopathological significance].
它在 ClinicalTrials.gov 上的全部试验(任何状态)31
- Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
- A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma
- Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors
- Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
- OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
- A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant Chemotherapy
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
- Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 8 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
这些数字背后的记录
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 8 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 4 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 33 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文11
- Implant derived high local concentration of magnesium inhibits tumorigenicity of osteosarcoma.
- Microwave-triggered organic sensitizer for synergistic dynamic/thermal therapy of osteosarcoma.
- AZIN1-dependent polyamine synthesis accelerates tumor cell cycle progression and impairs effector T-cell function in osteosarcoma.
- Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential.
- Dual Factor-Loaded Artificial Periosteum Accelerates Bone Regeneration.
- Establishment of orthotopic osteosarcoma animal models in immunocompetent rats through muti-rounds of in-vivo selection.
- Molecular Mechanism Underlying the Action of a Celastrol-Loaded Layered Double Hydroxide-Coated Magnesium Alloy in Osteosarcoma Inhibition and Bone Regeneration.
- Multifunctional 3D-printed scaffolds eradiate orthotopic osteosarcoma and promote osteogenesis via microwave thermo-chemotherapy combined with immunotherapy.
- Biodegradable photothermal thermosensitive hydrogels treat osteosarcoma by reprogramming macrophages.
- Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway.
- Pharmacological Inhibition of Core Regulatory Circuitry Liquid-liquid Phase Separation Suppresses Metastasis and Chemoresistance in Osteosarcoma.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
广州有 13 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- 分期
- I期
- 开始
- 2018-07
- 登记号
- NCT03594422
年龄 12 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、广州、武汉、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
早期论文(2016–2020 年)5
- Clinicopathological Outcomes and Prognosis of Elderly Patients (≥ 65 Years) with Gastric Gastrointestinal Stromal Tumors (GISTs) Undergoing Curative-Intent Resection: a Multicenter Data Review.
- Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review.
- Totally Laparoscopic Transluminal Resection for Gastrointestinal Stromal Tumors Located at the Cardiac Region.
- Tumor necrosis and >20 mitoses per 50 high-power fields can distinguish 'very high-risk' and 'highest-risk' within 'high-risk' gastric gastrointestinal stromal tumor.
- [Current status of surgical treatment of gastric gastrointestinal tumors: a national multi-center retrospective study].
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 23 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
广州有 14 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- 分期
- I期
- 开始
- 2025-12
- 登记号
- NCT07179679
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南充、南昌、广州、承德、苏州、西安、重庆
- 正在招募A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- 分期
- III期
- 开始
- 2021-10
- 登记号
- NCT05020236
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.
- Induction Chemotherapy-Related Covert Cardiac Remodeling in Pre-Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Retrospective Observational Study.
- C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.
它在 ClinicalTrials.gov 上的全部试验(任何状态)20
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
- Study of 3D189 in Patients With Hematologic Malignancies
- Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Daratumumab
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
广州有 8 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study of YK012 in B-cell Acute Lymphoblastic Leukemia
- 分期
- I/II期
- 开始
- 2024-09
- 登记号
- NCT06580301
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、广州、徐州、杭州、贵阳、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 23 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。
这些数字背后的记录
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 9 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
这些数字背后的记录
牵头的论文3
- Human herpesvirus meningitis type 7 combined with neuromyelitis optica spectrum disorders: a case report.
- Bilateral doughnut-shaped macular edema in a pregnant woman with neuromyelitis optica spectrum disorders.
- Correlation between ERα gene polymorphism and multiple sclerosis and neuromyelitis optica.
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。
这些数字背后的记录
牵头的论文3
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 8 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。
这些数字背后的记录
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 6 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 20 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 13 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.1%。
广州有 20 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Correlation of Microbiome and Metabonomics With IgA Nephropathy
- 分期
- 未注明
- 开始
- 2020-05
- 登记号
- NCT05190848
年龄 16 岁 至 65 岁(登记的条件)
牵头:广东省人民医院;另有 4 家列出的医院为研究中心广州
- 正在招募A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
- 分期
- III期
- 开始
- 2025-02
- 登记号
- NCT06819826
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州
- 正在招募A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- 分期
- III期
- 开始
- 2025-07
- 登记号
- NCT06963827
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文8
- Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study.
- Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy.
- Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis.
- The risk factor for adverse pregnancy outcomes and its impact on clinical effect in IgA nephropathy: A retrospective observational study.
- Genome-Wide Association Analysis of Protein-Coding Variants in IgA Nephropathy.
- Anomalous kinetics of galactose-deficient IgA incurring nephropathy revealed by cross-scale optical imaging.
- Systematic Microbiome Dysbiosis Is Associated with IgA Nephropathy.
- Increased proportion of follicular helper T cells is associated with B cell activation and disease severity in IgA nephropathy.
中文论文(未计入)2
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
- Correlation of Microbiome and Metabonomics With IgA Nephropathy
- Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
- Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
- A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy
- Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
- An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
- A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 9 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
牵头的论文4
- A novel subset of inflammation-related liver NK cells modulates immune responses in a murine model of primary biliary cholangitis.
- Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis.
- Spontaneous development of an autoimmune hepatitis - primary biliary cholangitis overlap syndrome in dnTGFβRII Aire-/- mice.
- Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis.
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
广州有 8 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
广东省人民医院
Guangdong Provincial People's Hospital
广州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Guangdong General Hospital; Guangdong Academy of Medical Sciences; Guangdong Provincial People's Hospital Heyuan Hospital; Guangdong General Hospital/Guangdong Academy of Medical Sciences; Guangdong General Hospital & Guangdong Academy of Medical Sciences; Guangdong Academy of Medical Sciences/Guangdong General Hospital; Ganzhou Hospital of Guangdong Provincial People's Hospital; Guangdong General Hospital and Guangdong Academy of Medical Sciences